oncology-therpeutics-2017-scientifictracks

Page 41

Notes:

allied

academies

J Med Oncl Ther 2017 Volume 2 | Issue 3

International Conference on

Oncology and Cancer Therapeutics

October 30- November 01, 2017 | Chicago, USA

Novel immunotherapy for non Hodgkin lymphoma using vaccine of cancer cells with anti-IL-19

antibodies

Manal Mohamed Saber

Minia University, Egypt

Background:

Non-Hodgkin’s lymphoma (NHL) is a group of

lymph proliferative malignant disorders with heterogeneous

histological and clinical features. Higher IL-19 serum levels

were associated with treatment failure and relapse in NHL.

Despite major advances in treatment, a proportion of patient

relapses highlighting the need for new immunotherapy.

Objective:

To develop a novel cancer vaccine expressing

anti-IL-19 mAbs in NHL

Methods:

The antitumour effect of the vaccine was

verified by therapeutic animal experiments

in vivo

. The

antitumour mechanism was analysed using flow cytometry,

immunohistochemistry, immunofluorescence, ELISA and

T-lymphocytes assays.

Results:

Novel cancer vaccine inhibited tumour growth and

extended the survival of the mice compared to vaccine-

untreated group. A strong T cell response by more CD4-

positive T cells, CD8-positive T cells, NK cells and tregs

appeared in the vaccine-treated group. Accompanying the

antitumor responses, there were increases in IFN-γ and

IL-12. Furthermore, novel cancer vaccine decreased the

tumour-induced apoptosis of T cells.

Conclusion:

This study has demonstrated a novel promising

cancer vaccine in tumour immunotherapy.

Speaker Biography

Manal Mohamed Saber has completed her PhD from Nottingham University. She is an

Associate Professor of Clinical Pathology, Minia University, Egypt. She has published

papers in peer reviewed journals and has been serving as an Editorial Board Member

of others.